Ascendis Pharma A/S
ASND
132 hedge funds and large institutions have $5.49B invested in Ascendis Pharma A/S in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 57 increasing their positions, 42 reducing their positions, and 23 closing their positions.
269% more call options, than puts
Call options by funds: $109M | Put options by funds: $29.5M
36% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 42
3.56% more ownership
Funds ownership: 99.39% → 102.94% (+3.6%)
1% more capital invested
Capital invested by funds: $5.41B → $5.49B (+$72.8M)
4% less funds holding
Funds holding: 138 → 132 (-6)
16% less funds holding in top 10
Funds holding in top 10: 19 → 16 (-3)
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$300M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$111M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$55.3M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$34.1M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$26.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$76.6M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$42.5M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$34.4M |
| 4 |
Millennium Management
New York
|
-$31.3M |
| 5 |
D.E. Shaw & Co
New York
|
-$28.9M |
ASND Hedge Fund Activity: Q2 2019 in Review
132 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2019, worth a combined $5.49B — up 1.3% from $5.41B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ASND and 18 opened new positions — a net loss of 5 holders — while 42 trimmed existing stakes and 57 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $300M. The largest seller was Perceptive Advisors, cutting an estimated $76.6M.
- 132 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2019, down from 138 in Q1 2019.
- Funds reported $5.49B of Ascendis Pharma A/S stock for Q2 2019, up 1.3% quarter-over-quarter.
- 18 funds opened new Ascendis Pharma A/S positions in Q2 2019 and 23 closed out, a net change of -5 holders.
- The largest Ascendis Pharma A/S buyer in Q2 2019 was T. Rowe Price Associates, an estimated $300M added.
- The largest Ascendis Pharma A/S seller in Q2 2019 was Perceptive Advisors, an estimated $76.6M sold.
Based on aggregated 13F filings for Q2 2019.